When people talk about “the celiac genes,” they usually mean HLA-DQ2 and HLA-DQ8. Almost everyone diagnosed with celiac disease carries one of these genetic risk patterns. But the reverse is not true: most people who carry them never develop the disease. That gap between genetic susceptibility and diagnosis is the key to understanding what these markers mean-and why a positive genetic result is not a verdict.
There is also a small technical correction to the shorthand in the headline. DQ2 and DQ8 are not single genes; they are HLA protein types encoded by particular combinations of variants in the HLA-DQA1 and HLA-DQB1 genes.
What DQ2 and DQ8 actually do
HLA stands for human leukocyte antigen. These molecules sit on certain cells and help the immune system identify protein fragments. In people with celiac disease, HLA-DQ2 or HLA-DQ8 can bind fragments of gluten and present them to immune cells in a way that contributes to an abnormal immune response. The resulting inflammation can damage the small intestine.
“DQ2” also covers more than one related type, especially DQ2.5 and DQ2.2. NIDDK reports that about 95% of people with celiac disease have DQ2.5; most of the remainder have DQ8. These figures describe people who already have celiac disease, not the likelihood that a carrier will get it.
Gluten-the trigger-is found in wheat, barley, and rye. The immune reaction is specific to celiac disease; it is not the same as a wheat allergy or non-celiac gluten sensitivity.
Why a common risk marker is not destiny
HLA-DQ2 and HLA-DQ8 are common in the general population. NIDDK estimates that about 30% of people have one of these types, while only about 3% of carriers develop celiac disease. Put plainly, a positive result identifies biological possibility, not illness.
These markers are important, but they are not the whole genetic story. Other genes and non-genetic influences are being studied, and scientists do not yet have a complete explanation for why one carrier becomes ill while another does not. A family history raises concern, but it still cannot tell whether a particular relative has the disease.
Symptoms do not settle the question either. Celiac disease can cause digestive problems, fatigue, anemia, or other symptoms, but some people have few obvious signs. And recurring discomfort after meals can have many causes; Earth and World’s guide to possible reasons for post-meal discomfort is a reminder that symptoms alone do not identify celiac disease.
What a genetic test can-and cannot-tell you
A genetic test checks for celiac-associated HLA types, usually from a blood sample or cheek swab. Its most useful result is often a negative one: if the relevant types are absent, celiac disease becomes very unlikely. That can help clinicians resolve an unclear evaluation or assess someone who has already stopped eating gluten.
A positive result has a different meaning. It says the person carries genetic susceptibility; it does not show that gluten has triggered disease, that the intestine is damaged, or that symptoms are caused by celiac disease. That is why genetic testing is generally not the first diagnostic step for someone eating a normal diet and being evaluated for suspected celiac disease.
A consumer-facing celiac genetic test can be a starting point for a conversation, but results need clinical context. Check what variants the test covers and discuss interpretation with a healthcare professional, especially if symptoms, blood tests, or biopsy findings point in different directions.
Diagnosis still depends on the clinical picture
For most people, evaluation starts with blood tests for celiac-associated antibodies. Depending on the results and circumstances, a clinician may recommend an upper endoscopy and small-intestine biopsies. The American College of Gastroenterology’s 2023 guideline describes HLA testing as useful in selected situations, such as conflicting blood-test and biopsy results-not as a stand-alone confirmation.
One practical detail matters: standard antibody testing is most informative while a person is still eating gluten. Going gluten-free first can make tests less reliable. If someone has already changed their diet, a clinician may consider HLA testing to help decide whether further evaluation, potentially including a supervised gluten challenge, makes sense. Do not restart gluten or make a major diet change solely on the basis of an online result.
The sensible takeaway
DQ2 and DQ8 explain much of the inherited susceptibility behind celiac disease, but their real value is often misunderstood. A positive test marks possibility, not certainty; a negative test can be far more informative when a clinician is trying to rule the disease out. Neither result replaces a proper diagnostic assessment.
If you have persistent symptoms, a close relative with celiac disease, or an inconclusive workup, ask a healthcare professional which test answers the question you actually have. Genetics can help narrow the path. It cannot, by itself, tell the whole story.
